Представлен сокращенный адаптированный вариант российских федеральных клинических рекомендаций по диагностике и лечению саркоидоза. Материал подготовлен группой экспертов и учитывает все имеющиеся на сегодняшний день мировые достижения в изучении данного заболевания и огромный собственный клинический опыт авторов. В первой части раскрыты вопросы этиологии, патогенеза, эпидемиологии, клинических проявлений саркоидоза при вовлечении в процесс различных органов и систем. Во второй части

No abstract

Sarcoidosis is epithelioid cell granulomatosis of unknown etiology. All the schemes of its treatment are of a recommendatory nature. Methotrexate (MTT) is considered a second-line drug in the treatment of sarcoidosis.Methods. A retrospective observational study of patients with progressive sarcoidosis (n = 104), treated with MTT once a week, was carried out. Clinical, laboratory, functional and radiation parameters were evaluated with an interval of 3 months ≤ 1 year.Results. The use of MTT was accompanied by an improvement in the radiation picture (64.1% by the end of the year), an improvement not only in spirometry parameters, starting from the 3rd month (54.7%), but also in the general condition of the patients (63.8% – at the 6th month). Adverse reactions with drug withdrawal were most often observed (15.4%) during the first 3 months, and subsequently their frequency decreased.Conclusion. According to the results of the study, it was shown that methotrexate can be recommended for further use in progressive sarcoidosis, as well as in patients, who have previously received systemic glucocorticosteroids.

No abstract

No abstract